
Nyxoah (NASDAQ:NYXH) reported 13% sequential worldwide net revenue growth in the first quarter of 2026, driven primarily by continued adoption of its Genio system in the United States, where the company is in its second full quarter of commercialization.
Chief Executive Officer Olivier Taelman said the company delivered on its commitment to generate 25% sequential U.S. revenue growth from the fourth quarter of 2025 to the first quarter of 2026. He cited momentum across surgeon training, account activation, prior authorization submissions and procedure volumes.